Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nova-EPO
- Development stage
- Preclinical
- Lead developer
- Genovo
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Nova-EPO is a recombinant fusion protein consisting of an erythropoietin (EPO) polypeptide fused to a mutated Fc fragment of human IgG. Developed by Genoxa, it is designed as an erythropoiesis-stimulating agent (ESA) for the treatment of anemia. The drug acts as an agonist for the erythropoietin receptor (EPOR), mimicking the action of endogenous erythropoietin to stimulate the proliferation and differentiation of erythroid progenitor cells in the bone marrow, thereby increasing red blood cell production. The incorporation of a mutated Fc fragment is intended to extend the protein's circulating half-life through neonatal Fc receptor (FcRn)-mediated recycling, potentially allowing for a more convenient dosing schedule compared to first-generation recombinant human erythropoietins. Nova-EPO is currently in the preclinical stage of development.
- Other names
- EPO-Fc fusion proteinErythropoietin-Fc fusion protein
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on Nova-EPO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nova-EPO.